These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. The role of natalizumab in the treatment of multiple sclerosis. Coyle PK Am J Manag Care; 2010 Jun; 16(6 Suppl):S164-70. PubMed ID: 20615052 [TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis and Natalizumab. Fiore D Am J Ther; 2007; 14(6):555-60. PubMed ID: 18090880 [TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of natalizumab for formulary consideration. Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228 [TBL] [Abstract][Full Text] [Related]
12. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Goodin DS; Cohen BA; O'Connor P; Kappos L; Stevens JC; Neurology; 2008 Sep; 71(10):766-73. PubMed ID: 18765653 [TBL] [Abstract][Full Text] [Related]
13. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis. Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116 [TBL] [Abstract][Full Text] [Related]